Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 6/20 | 0.63 |
| ▸ | MYC | P01106 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ACLY | P53396 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CCR2 | P41597 | 1/20 | 0.48 |
| ▸ | METAP2 | P50579 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7587628 | 0.85 | NPC1 (0.70) | WDR5MYCNPC1TSHRACLY | |
| SCHEMBL4192562 | 0.83 | WDR5 (0.58) | WDR5MYCACLY | |
| SCHEMBL4190139 | 0.80 | WDR5 (0.58) | WDR5MYCACLY | |
| SCHEMBL4197378 | 0.78 | WDR5 (0.54) | WDR5MYCACLY | |
| SCHEMBL21761109 | 0.75 | LMNA (0.73) | ACLYLMNA | |
| SCHEMBL22095987 | 0.75 | SMN1; SMN2 (0.78) | NPC1TSHRLMNA | |
| SCHEMBL4190669 | 0.75 | NPC1 (0.65) | WDR5NPC1TSHRLMNACCR2 | |
| SCHEMBL4192352 | 0.75 | NPC1 (0.58) | NPC1TSHRACLY | |
| SCHEMBL4183289 | 0.74 | NPC1 (0.60) | WDR5NPC1TSHRLMNACCR2 | |
| SCHEMBL329987 | 0.73 | TP53 (0.73) | WDR5MYCACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060106089-A1 | Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use | VTVX HOLDINGS II LLC | 2006-05-18 | — | — | US | claimed |
| US-20090247536-A1 | Bissulfonamide Compounds As Agonists Of GalR1, Compositions, And Methods Of Use | MJALLI ADNAN M M | 2009-10-01 | — | — | US | disclosed |
| US-20090247536-A1 | Bissulfonamide Compounds As Agonists Of GalR1, Compositions, And Methods Of Use | MJALLI ADNAN M M | 2009-10-01 | — | — | US | disclosed |
| US-20090247536-A1 | Bissulfonamide Compounds As Agonists Of GalR1, Compositions, And Methods Of Use | MJALLI ADNAN M M | 2009-10-01 | — | — | US | disclosed |
| US-7582673-B2 | Benzo[b]thiophene-2-sulfonic acid [2-(2-chloro-5-trifluoromethylbenzenesulfonylamino)phenyl] amide; agonists of GalR1; useful in treating neuropathic pain or cancer | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582673-B2 | Benzo[b]thiophene-2-sulfonic acid [2-(2-chloro-5-trifluoromethylbenzenesulfonylamino)phenyl] amide; agonists of GalR1; useful in treating neuropathic pain or cancer | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582673-B2 | Benzo[b]thiophene-2-sulfonic acid [2-(2-chloro-5-trifluoromethylbenzenesulfonylamino)phenyl] amide; agonists of GalR1; useful in treating neuropathic pain or cancer | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1809619-A1 | BISSULFONAMIDE COMPOUNDS AS AGONISTS OF GALR1, COMPOSITIONS, AND METHODS OF USE | Transtech Pharma, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060106089-A1 | Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use | VTVX HOLDINGS II LLC | 2006-05-18 | — | — | US | disclosed |
| WO-2006047302-A1 | BISSULFONAMIDE COMPOUNDS AS AGONISTS OF GALR1, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106089-A1 | Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use | GALR1, GALR3, GALR2 | WDR5 4553/4885MYC 2089/4885NPC1 4565/4885 |
| US-20090247536-A1 | Bissulfonamide Compounds As Agonists Of GalR1, Compositions, And Methods Of Use | GALR1, GALR3, GALR2 | WDR5 4553/4885MYC 2089/4885NPC1 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.